Status:
NOT_YET_RECRUITING
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Dilated Cardiomyopathy (DCM)
Heart Failure
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopath...
Detailed Description
Background: Immune system activation and myocardial fibrosis are widely observed in patients with heart failure, whether it is ischemic or non-ischemic heart failure. Therefore, targeting inflammation...
Eligibility Criteria
Inclusion
- Age between 18 years old and 75 years old, diagnosed with dilated cardiomyopathy.
- Able to verbally confirm that he/she understands the risks, benefits and treatment options of the iCDC trial. He/she or his/her legal representative provides written informed consent before participating in the clinical trial.
- Diagnosed with Heart Failure with reduced ejection fraction (HFrEF), optimized drug therapy (under maximum tolerance of GDMT) for at least 3 months, left ventricular ejection fraction \<35%, NYHA functional class ⅢB-IV, INTERMACS class 3-6.
- Blood test: hematocrit \>30%, lymphocytes \>0.5×10\^9/L, platelets \>60×10\^9/L.
Exclusion
- History of myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks before enrollment.
- CRT implanted within 12 weeks before enrollment or intended to implant CRT device.
- Previous heart transplantation or implantation of a ventricular assist device or similar device, or planned implantation of a ventricular assist device or similar device.
- Heart failure caused by ischemic cardiomyopathy, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, long-standing hypertension, congenital structural heart disease, or uncorrected primary valvular disease.
- Symptomatic bradycardia or second/third degree heart block.
- Active autoimmune disease requiring immunosuppressive therapy.
- Pulmonary Embolism (PE), Deep Vein Thrombosis(DVT), or recurrent embolism.
- A history of tuberculosis.
- History of severe renal failure or need for dialysis, creatinine \>2.5 mg/dl.
- Uncorrected thrombocytopenia or systemic coagulopathy (platelet count \< 50,000, INR \> 2.5, or aPTT \> 2.5 times control in the absence of anticoagulation), or active bleeding and uncorrectable coagulopathy.
- Aspartate aminotransferase or alanine aminotransferase levels greater than 5.0 times the upper limit of normal (ULN), total bilirubin \>3 mg/dl.
- Systolic blood pressure \<90 mmHg.
- History of concurrent severe infection, hepatobiliary obstruction, or malignancy.
- Infections: Active hepatitis B (PCR-detected hepatitis B virus DNA copies \> 1000), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection at screening; uncontrolled systemic fungal, bacterial, viral, or other pathogen infection.
- Severe hemodynamic instability (eg, shock).
- Women who are pregnant or may become pregnant.
- Contraindications to study drugs or tests.
Key Trial Info
Start Date :
April 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT06902896
Start Date
April 7 2025
End Date
June 30 2028
Last Update
April 8 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.